This document is a patent application, not a regulatory rule or guidance. It describes novel psilocin derivatives, specifically carbohydrate and amino acid conjugates, and their potential therapeutic applications. The application details the chemical structures (Formula I) and lists inventors Raimar Loebenberg, Chuanjun Gao, and Rong Ling. The claimed uses include treatment for depression, addiction (tobacco, opiate, cocaine), alcoholism, PTSD, and various pain syndromes.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signals potential future developments in the pharmaceutical industry related to psychedelic-assisted therapies and novel drug development. Companies involved in pharmaceutical research and development, particularly in the areas of neuroscience and mental health, should be aware of this application as it may impact intellectual property landscapes and future market opportunities.